See more : Daishin Securities Co., Ltd. (003545.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Imunon, Inc. (CLSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imunon, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Benessere Capital Acquisition Corp. (BENE) Income Statement Analysis – Financial Results
- Cranswick plc (CWK.L) Income Statement Analysis – Financial Results
- Anadolu Hayat Emeklilik Anonim Sirketi (AELIY) Income Statement Analysis – Financial Results
- ELAN Microelectronics Corporation (2458.TW) Income Statement Analysis – Financial Results
- Virgin Money UK PLC (VMUK.L) Income Statement Analysis – Financial Results
Imunon, Inc. (CLSN)
About Imunon, Inc.
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 11.25M | 12.32M | 2.51M | 0.00 | 0.00 | 0.00 | 3.42K | 100.00K | 174.18K | 121.26K | 74.01K |
| Cost of Revenue | 720.01K | 731.63K | 702.92K | 11.34M | 13.07M | 11.07M | 13.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.67M | 8.11M | 2.10M | 0.00 | 0.00 | 0.00 | -39.23K | 0.00 | 136.50K | 46.73K | 64.41K |
| Gross Profit | -720.01K | -231.63K | -202.92K | -10.84M | -12.57M | -10.57M | -12.58M | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 4.58M | 4.21M | 405.34K | 0.00 | 0.00 | 0.00 | 42.65K | 100.00K | 37.68K | 74.52K | 9.60K |
| Gross Profit Ratio | 0.00% | -46.33% | -40.58% | -2,168.96% | -2,513.06% | -2,113.10% | -2,515.74% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 40.72% | 34.15% | 16.17% | 0.00% | 0.00% | 0.00% | 1,247.13% | 100.00% | 21.63% | 61.46% | 12.97% |
| Research & Development | 11.29M | 11.73M | 10.62M | 11.34M | 13.07M | 11.87M | 13.08M | 14.62M | 14.66M | 14.97M | 9.36M | 15.77M | 19.86M | 14.71M | 13.68M | 12.01M | 8.23M | 9.35M | 10.08M | 11.53M | 8.18M | 5.00M | 4.08M | 2.24M | 1.00M | 1.53M | 185.97K | 94.01K |
| General & Administrative | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 0.00 | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 0.00 | 0.00 | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 390.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 5.15M | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 3.47M | 5.13M | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Other Expenses | 0.00 | 5.40M | 1.62M | -1.30M | 3.19M | 3.63M | 651.97K | 733.00K | -259.45K | 265.89K | -2.53K | -1.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 14.08M | 13.49M | 15.00M | 13.30M | 9.84M | 7.29M | 4.94M | 2.40M | 4.05M | 2.47M | 1.43M |
| Cost & Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 20.75M | 21.60M | 17.11M | 13.30M | 9.84M | 7.29M | 4.90M | 2.40M | 4.19M | 2.52M | 1.50M |
| Interest Income | 960.55K | 502.58K | 18.15K | 66.55K | 442.99K | 331.78K | 26.04K | 31.26K | 186.32K | 1.02M | 748.95K | 0.00 | 174.06K | 32.29K | 46.16K | 221.71K | 0.00 | 636.56K | 299.25K | 0.00 | 30.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.57M | 557.00K | 1.29M | 1.39M | 712.03K | 91.76K | 693.00K | 1.36M | 1.33M | 915.24K | 307.00K | 501.86K | 31.52K | 94.92K | 141.61K | 49.42M | 1.10M | 179.59K | 0.00 | -13.27M | -9.75M | -6.92M | 0.00 | 0.00 | 199.35K | 0.00 | 85.51K |
| Depreciation & Amortization | 720.01K | 731.63K | 702.92K | 741.52K | 721.67K | 356.86K | 553.01K | 1.03M | 424.97K | 369.33K | 339.23K | 281.49K | 176.86K | 172.98K | 109.65K | 69.47K | -39.11K | -341.29K | -321.39K | -275.68K | 100.53K | 82.44K | 68.85K | 39.48K | -100.00K | 24.29K | 24.17K | 18.55K |
| EBITDA | -19.88M | -31.71M | -20.88M | -21.30M | -16.55M | -21.23M | -19.76M | -20.30M | -20.67M | -23.79M | -6.99M | -25.92M | -22.54M | -18.61M | -15.80M | -11.58M | -13.13M | -9.84M | -9.50M | -14.78M | -13.20M | -9.79M | -7.26M | -4.86M | -2.40M | -3.99M | -2.37M | -1.40M |
| EBITDA Ratio | 0.00% | -3,905.20% | -3,877.00% | -3,795.72% | -3,242.17% | -3,349.10% | -3,447.48% | -3,983.40% | -4,098.99% | -4,335.91% | -2,865.17% | 0.00% | -1,133.39% | 0.00% | 0.00% | -463.01% | 0.00% | -94.55% | -77.14% | -589.83% | 0.00% | 0.00% | 0.00% | -142,016.75% | -2,300.00% | -2,296.79% | -1,960.88% | -1,936.39% |
| Operating Income | -21.03M | -24.92M | -21.01M | -18.49M | -20.57M | -21.07M | -18.47M | -20.65M | -20.85M | -24.72M | -15.41M | -22.14M | -23.02M | -19.64M | -17.01M | -11.55M | -13.59M | -8.49M | -9.28M | -14.60M | -13.30M | -9.84M | -7.29M | -4.90M | -2.30M | -4.01M | -2.39M | -1.42M |
| Operating Income Ratio | 0.00% | -4,984.40% | -4,201.40% | -3,697.28% | -4,113.09% | -4,213.01% | -3,693.69% | -4,130.00% | -4,169.36% | -4,943.04% | -3,082.30% | 0.00% | -1,150.94% | 0.00% | 0.00% | -461.98% | 0.00% | -75.43% | -75.32% | -582.51% | 0.00% | 0.00% | 0.00% | -143,171.08% | -2,300.00% | -2,303.92% | -1,974.89% | -1,922.52% |
| Total Other Income/Expenses | 235.07K | -12.54M | -1.15M | -4.84M | 1.90M | -1.24M | -1.93M | -1.40M | -1.61M | -779.08K | 7.16M | -4.43M | -203.91K | 818.99K | 1.01M | -236.80K | -483.23K | 902.40K | -96.89K | 613.90K | 30.38K | 86.61K | 363.65K | 349.24K | -100.00K | -187.48K | -657.19K | -510.69K |
| Income Before Tax | -20.80M | -37.47M | -22.15M | -23.33M | -18.67M | -22.30M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -16.00M | -11.79M | -14.07M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Income Before Tax Ratio | 0.00% | -7,493.00% | -4,430.60% | -4,665.88% | -3,733.60% | -4,460.49% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| Income Tax Expense | -1.28M | -1.57M | -1.38M | -1.85M | -1.82M | -10.42M | 1.93M | 1.40M | 1.61M | 779.08K | 1.00 | 4.43M | 203.91K | -818.99K | -806.00K | 236.80K | -49.42M | -1.91M | 8.69M | -613.90K | 13.27M | 9.75M | 6.92M | 4.55M | 2.40M | 187.48K | 657.19K | 510.69K |
| Net Income | -19.51M | -35.90M | -20.77M | -21.48M | -16.85M | -11.88M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -15.19M | -11.79M | 35.35M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Net Income Ratio | 0.00% | -7,179.60% | -4,153.80% | -4,296.71% | -3,370.31% | -2,376.67% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| EPS | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.43 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 3.11K | -668.10 | -765.29 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -105.01 | -1.52K | -1.09K |
| EPS Diluted | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.42 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 2.90K | -668.10 | -760.54 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -193.97 | -1.52K | -1.09K |
| Weighted Avg Shares Out | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 11.36K | 11.35K | 11.35K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 40.00K | 2.00K | 1.78K |
| Weighted Avg Shares Out (Dil) | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 12.18K | 11.35K | 11.42K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 21.66K | 2.00K | 1.78K |
CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares of its common stock at a purchase...
Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA
Why Celsion Stock Is Surging Today
Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock. Zacks analyst David Bautz highlighted the business update Celsion provided at the end of March.
Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021
LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the company reported a cash position of $56.9 million as of December 31, 2021 during its earnings...
Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript
Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript
Celsion Corporation Reports 2021 Financial Results and Provides Business Update
Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time
Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss...
Celsion (CLSN) Stock: 1-For-15 Reverse Split Goes Into Effect
A 1-for-15 reverse split of Celsion Corporation (NASDAQ: CLSN) stock has gone into effect. These are the details.
Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses
Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024
Celsion Corporation Announces Stock Consolidation
LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse stock split) of...
Source: https://incomestatements.info
Category: Stock Reports